Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia

Metabolic Brain Disease
Gersilene Valente de OliveiraDanielle Silveira Macêdo


Tardive dyskinesia (TD) is an iatrogenic syndrome being a significant adverse outcome of typical and atypical antipsychotic therapy. Recently we demonstrated that vitamins B (B1, B6, B12 alone or in combination) were able to prevent haloperidol-induced orofacial dyskinesia (OD) possibly by their antioxidant activity in the striatum, using a well-established model of TD. Here, based on the fact that alterations in cholinergic neurotransmission are related to TD pathophysiology and that vitamins B seems to influence brain cholinergic neurotransmission, we decided to investigate the effects of vitamins B1, B6, B12 and their association, vitamin B cocktail in haloperidol-induced cholinergic alterations, evaluated by alterations in acetylcholinesterase (AChE) activity, in striatum, prefrontal cortex and hippocampus, as a way to determine the participation of cholinergic neurotransmission, in these vitamins antidyskinetic mechanism. Haloperidol 1 mg/kg i.p. daily administration during 21 days to Wistar rats caused OD while decreased AChE activity in all brain areas studied. Vitamins B administration (B1:B6:B12 at 60:60:0.6 mg/kg, s.c) alone and vitamin B cocktail co-administered with haloperidol prevented OD development and increased...Continue Reading


Oct 1, 1992·Pharmacology, Biochemistry, and Behavior·H SasakiK Sekizawa
Nov 1, 1989·Archives of General Psychiatry·D V Jeste, J B Lohr
Jun 1, 1988·Biological Psychiatry·S P MahadikS E Karpiak
Aug 1, 1983·Psychological Medicine·E C JohnstoneS J Gamble
Mar 4, 1999·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·M C OlianasP Onali
Feb 19, 2002·Neurochemistry International·Gary E Gibson, Hui Zhang
May 24, 2003·Neuropharmacology·Pattipati S NaiduShrinivas K Kulkarni
Jul 1, 1961·Biochemical Pharmacology·G L ELLMANR M FEATHER-STONE
Dec 3, 2004·The Journal of Pharmacology and Experimental Therapeutics·Carrie K JonesHarlan E Shannon
Sep 15, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Segev Barak, Ina Weiner
Oct 2, 2007·Trends in Neurosciences·Antonio PisaniD James Surmeier
Dec 7, 2007·The Journal of Clinical Psychiatry·Vladimir LernerEliezer Witztum
Jan 1, 1981·Neurochemistry International·M Ebadi
Feb 24, 2011·Frontiers in Neuroanatomy·Paola BonsiAntonio Pisani
Apr 9, 2011·Journal of Neural Transmission·Romaiana Picada PereiraJoão B T Rocha
Sep 16, 2011·Behavioural Pharmacology·Danielle Silveira MacêdoAndré Férrer Carvalho
Nov 15, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Antonio CerasaAldo Quattrone
Nov 30, 2011·Current Drug Safety·Michele Raja


Jul 29, 2017·Expert Review of Neurotherapeutics·Haitham SalemAntonio L Teixeira
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo
Mar 23, 2017·Canadian Journal of Physiology and Pharmacology·Dayane Pessoa de AraújoFausto Pierdoná Guzen

Related Concepts

Etat Marbre
Antipsychotic Effect
Vitamin B Complex
Rats, Wistar
Rats, Laboratory

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here